Carlsons Super Omega-3 Gems 1000 mg 250 softgels

Omega-3 fatty acids are provided in these easy-to-swallow softgels. Omega-3s support blood circulation and the integrity of blood arteries and veins, normal brain functioning, permeability and flexibility of cell membranes, and help protect the photoreceptor cells in the retina.

• Concentrate
• Purity / Potency / Freshness Guaranteed
• 500 mg EPA & DHA
• Norwegian source

Supplement Facts
Serving Size: 1 Softgel
Servings per Container: 250

Amount per Serving:
Calories 9 per gelcap
Calories from Fat 9 per gelcap
Total Fat 1 g
Vitamin E Natural (d-Alpha Tocopherol) 10 IU
Omega-3 Fatty Acids (from fish oil) 600 mg
EPA (Eicosapentaenoic Acid) 300 mg
DHA (Docosahexaenoic Acid) 200 mg
Other Omega-3s 100 mg

Other Ingredients: Soft Gel Shell: Beef gelatin, glycerin and water.

Directions: Take one soft gel one to five times daily, with meals.

Carlson SUPER OMEGA-3 GEMS™ soft gels contain a full gram of a concentrated fish body oils that are derived from deep, cold water fish, particularly containing Omega-3's EPA and DHA.

Purity guaranteed by Carlson.
This product is regularly tested (using AOAC international protocols) for -freshness, potency and purity by an independent, FDA-registered laboratory and -has been determined to be fresh, fully potent and free of detrimental levels of -mercury, cadmium, lead, PCB’s and 28 other contaminants.

To Promote Cardiovascular, Joint, Brain & Vision Health**

** This statement has not been evaluated by the FDA. This product is not intended to diagnose, treat, cure or prevent any disease.

Related Studies

Dementia /Cognitive Memory

This randomized study was done to see if fish consumption and intake of omega-3 fatty acids help protect against Alzheimer’s Disease.

The conclusion of the study was that intake n-3 fatty acids and weekly consumption of fish may reduce the risk of incidence of memory/cognition decline.
Ref: Morris MC, Evans DA, Bienias JL, et al. Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. Arch Neurol. 2003;60(7):940–946.

Docosahexaenoic Acid Supplementation and Cognitive Decline in Alzheimer Disease

Study conclusion was that dietary intake of n-3 polyunsaturated fatty acids supported heterogeneity in cognitive aging and, possibly, in Alzheimer disease.
Ref: Whalley LJ, Deary IJ, Starr JM, et al. n-3 Fatty acid erythrocyte membrane content, APOE epsilon4, and cognitive variation: an observational follow-up study in late adulthood. Am J Clin Nutr. 2008;87(2):449–454.

Macular Support

Omega-3 Fatty Acids & Lower Risk of Macular Degeneration: 2011 Study
This 10 year study reviewed the diet of nearly 40,000 women, health professionals whose age averaged 54.6 years. More than 38,000 of the participants were free of macular degeneration, measured by incident AMD and a reduction of 20/30 or worse. 235 cases of AMD were confirmed in the ten years of follow-up.

The study conclusion substantiated earlier findings that a diet that regularly including omega-3 fatty acids significantly lowered risk of age related macular degeneration in women.
Researchers: William G. Christen, ScD; Debra A., et al. Published: Dietary omega-3 fatty acid and fish intake and incident age-related macular degeneration in women. Arch Ophthalmol. 2011;129(7):921-929

Omega-3 (2009) Higher Intake Reduces Risk of Developing Macular Degeneration
This longitudinal study was published in 2009, and investigated whether higher omega-3 intake is associated with a lower risk of developing macular degeneration. The study investigated the progression of the condition in 1837 people over 12 years. The researchers started with "before" data based on a diet questionnaire.

The conclusion of the researchers was that patients who reported the greatest omega-3 consumption were 20% less likely than their peers to develop AMD over the 12 year period.
Researchers: John Paul SanGiovanni and associates, Published 2009, American Journal of Clinical Nutrition.

Omega-3 Fatty Acid Intake Reduces Risk of Macular Degeneration 2008 Studies
This meta-analysis published in the June issue of Archives of Ophthalmology determined that a higher intake of the omega-3 fatty acids EPA and DHA reduced the risk of age-related macular degeneration (AMD).

A another study published in the August issue of the American Journal of Clinical Nutrition is the first in Europeans to show a beneficial association between neovascular AMD and the consumption of oily fish (e.g. mackerel, tuna, salmon, sardines, and herring)(2). The study, funded in part by the European Commission and the Macular Disease Society UK, is consistent with results from studies in the US and Australia.

In summary, the consumption of oily fish at least once a week was linked to a 50% reduction in the risk of developing wet AMD. Further, people who consumed at least 300 mg per day of DHA and EPA were 69% less likely to have wet AMD then those consuming less.

Retinitis Pigmentosa

Further evaluation of docosahexaenoic acid in patients with retinitis pigmentosa
Patients taking both Vitamin A with higher dietary omega-3 intake had visual field decline retarded by 40-50%.
Berson EL, et al., Arch Ophthalmol. 2004 Sep;122(9):1306-14

Glaucoma

Angle closure surveys in Greenland Eskimos
Greenland Eskimos with high level of omega-3 in diet have correspondingly less open angle glaucoma.
Albrick, P.H., Canadian Journal of Ophthalmology 8 (1973): 260-64.

Rheumatoid Arthritis

The role of fish oils in the treatment of rheumatoid arthritis
Conclusion that fish oils reduce inflammation in double-blind research
Leland LG and associates, Drugs. 2003;63(9):845-53

Dry Eyes

Relation between dietary n–3 and n–6 fatty acids and clinically diagnosed dry eye syndrome in women
higher dietary intake of n–3 FAs is associated with a decreased incidence of DES in women. These findings are consistent with anecdotal clinical observations and postulated biological mechanisms.
Am J Clin Nutr.2005; 82: 887-893

Stargardt's Disease

DHA supplementation for late onset Stargardt disease
Some improvement in vision for Stargardt's supplementing with omega-3 for six months or more.
Giuseppe Querques and associates, Clinical Ophthalmology. 2010; 4: 575–580